Table 1. Demographic and clinical data.

Variables	Whole series (N=28)	Group A (chemo) (N=17)	Group B (WBRT + chemo) (N=11)	P value
Gender, n (%)				0.903
Male	20 [71]	12 [71]	8 [73]
Female	8 [29]	5 [29]	3 [27]
Age, years at diagnosis (mean ± SD)	55.57±8.68	55.79±8.55	55.24±9.30	0.865
Smokers, n [%]	26 [93]	15 [89]	11 [100]	0.238
Smoking, pack-year (mean ± SD)	35.31±8.94	32.17±27.74	40.00±15.09	0.418
Brain metastases at diagnosis (n), median [range]	4 [3–5]	4 [3–5]	3 [3–5]	0.697
Patients with extracranial metastases at diagnosis, n [%]	20 [71]	11 [61]	9 [80]	0.336
Number of extracranial organs affected, median, [range]	2 [0–4]	2 [0–4]	1 [0–4]	0.147
Steroids treatment, n [%]				0.007
Yes	20 [71]	9 [53]	11 [100]
No	8 [29]	8 [47]	0
DS-GPA 1–4, median [range]	2 [1–4]	2 [1–4]	2 [1–3.5]	0.394
KPS 0–100, median [range]	90 [70–100]	80 [70–100]	90 [70–100]	0.201

WBRT, whole brain radiotherapy; SD, standard deviation; DS-GPA, diagnosis-specific graded prognostic assessment; KPS, Karnofsky Performance Scale.